Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis

Samuel D Johnson, Omalla A Olwenyi, Namita Bhyravbhatla, Michellie Thurman, Kabita Pandey, Elizabeth A Klug, Morgan Johnston, Shetty Ravi Dyavar, Arpan Acharya, Anthony T Podany, Courtney V Fletcher, Mahesh Mohan, Kamal Singh, Siddappa N Byrareddy

ORCID number: Samuel D Johnson 0000-0002-9978-6968; Omalla A Olwenyi 0000-0002-5497-421X; Namita Bhyravbhatla 0000-0002-6164-8308; Michellie Thurman 0000-0002-7699-1870; Kabita Pandey 0000-0002-2687-1831; Elizabeth A Klug 0000-0003-3689-6104; Morgan Johnston 0000-0002-0049-160X; Shetty Ravi Dyavar 0000-0002-2141-7214; Arpan Acharya 0000-0003-2721-1062; Anthony Podany 0000-0002-3971-0379; Courtney V Fletcher 0000-0002-3703-7849; Mahesh Mohan 0000-0003-4360-3277; Kamal Singh 0000-0001-6153-8929; Siddappa N Byrareddy 0000-0002-6889-4640.

Author contributions: Johnson SD and Olwenyi OA contributed equally to the conception, review of literature, and drafting of the manuscript; all authors contributed to the writing and editing of the manuscript and approved the final version of the manuscript.

Supported by National Institutes of Health grants, No. R01AI129745, No. R21MH13455, No. R01DA052845, and No. R01AI13883 (to Byrareddy SN).

Conflict-of-interest statement: Authors declare no conflict of interests for this article.

Open-Access: This article is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited and is not altered, transformed, or built upon.

Abstract

The emergence and rapid spread of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 180 million confirmed cases resulting in over 4 million deaths worldwide with no clear end in sight for the coronavirus disease 19 (COVID-19) pandemic. Most SARS-CoV-2 exposed individuals experience mild to moderate symptoms, including fever, cough, fatigue, and loss of smell and taste. However, many individuals develop pneumonia, acute respiratory distress syndrome, septic shock, and multiorgan dysfunction. In addition to these primarily respiratory symptoms, SARS-CoV-2...
INTRODUCTION

Starting from late 2019 and through 2020, a novel coronavirus, the causative agent of coronavirus disease 19 (COVID-19), initiated one of the deadliest global pandemics warranting extensive panic for the underprepared global health system[1-4]. The pandemic has claimed countless lives (approximately 4 million deaths worldwide of 188 million confirmed cases as of July 15, 2021) and presented unprecedented socio-economic losses[5-8]. The primary mode of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission is airborne, with infectious droplets gaining access into the host respiratory tract. Subsequently, standard clinical indicators comprise fever, cough, fatigue, chills, nausea, headache, dyspnea. Additionally, the loss of taste or smell often ensues[9,10]. Coronavirus infections primarily target the upper respiratory tract, but they also manifest in other regions such as the gastrointestinal tract (GIT). Within the GIT, additional symptoms such as lack of appetite, vomiting, abdominal pain, and diarrhea have been observed in some individuals[11,12].

SARS-CoV-2 has been shown to infect GIT cells such as human gut enterocytes[13]. SARS-CoV-2 RNA has also been detected in gastrointestinal glandular epithelial cells [14-17]. During infection, compromised gastrointestinal symptom involvement has worse clinical outcomes and takes longer to recover than those with only respiratory symptoms[18]. Furthermore, infection can also infiltrate the central nervous system, which may damage the blood-brain barrier and the neuron's synapses. Resultant inflammation and neurodegeneration in the brain stem can further prevent efferent signaling to cranial nerves, leading to the loss of anti-inflammatory signaling and normal respiratory and gastrointestinal functions. Additionally, SARS-CoV-2 can infect enterocytes resulting in gut damage followed by microbial dysbiosis and translocation of bacteria and their byproducts across the damaged epithelial barrier. As a result, this exacerbates pro-inflammatory responses both locally and systemically, resulting in impaired clinical outcomes. Recent evidence has highlighted the complex interactions that mutually modulate respiratory, neurological, and gastrointestinal function. In this review, we discuss the ways SARS-CoV-2 potentially disrupts the gut-brain-lung axis. We further highlight targeting specific responses to SARS-CoV-2 for the development of novel, urgently needed therapeutic interventions. Finally, we propose a prospective related to the individuals from Low- and Middle-Income countries. Here, the underlying propensity for heightened gut damage/microbial translocation is likely to result in worse clinical outcomes during this COVID-19 pandemic.

Key Words: SARS-CoV-2; Gut; Microbiome; Lungs; Brain; Therapeutics

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Severe acute respiratory syndrome coronavirus 2 has spread rapidly, infecting and killing millions worldwide. In addition to respiratory symptoms, coronavirus disease 19 (COVID-19) is associated with enterocyte infection leading to intestinal inflammation, gut barrier damage, and microbial dysbiosis exacerbating the systemic inflammatory response. Viral infiltration to the central nervous system from cranial nerve innervation of the lungs and gut can also cause neuroinflammation and degeneration, which further dysregulates gut and lungs. This review summarizes recent findings on COVID-19 pathogenesis in the gut-brain-lung axis and offers therapeutic interventions to improve clinical outcomes.

Citation: Johnson SD, Olwenyi OA, Bhyravbhata N, Thurman M, Pandey K, Klug EA, Johnston M, Dyavar SR, Acharya A, Podany AT, Fletcher CV, Mohan M, Singh K, Byrareddy SN. Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. World J Gastroenterol 2021; 27(29): 4763-4783

URL: https://www.wjgnet.com/1007-9327/full/v27/i29/4763.htm

DOI: https://dx.doi.org/10.3748/wjg.v27.i29.4763
symptoms[18-20]. Subsequently, patients who test positive for viral RNA in feces have poor viral clearance and prolonged delays for infection resolution[21]. SARS-CoV-2 tropism in the lungs and GIT is supported by abundant cellular viral entry receptors such as the angiotensin-converting enzyme-2 (ACE2). ACE2 exists in abundance on the epithelia of the lungs and small intestine (ileum)[22,23]. ACE2 catalyzes the conversion of angiotensin II into angiotensin 1-7; it is crucial for maintaining gut balance through regulation of amino acid homeostasis, innate immunity, the balance of the intestinal microbiome, and by limiting diarrhea[24,25].

The gut is the largest immune organ and is a crucial interconnecting hub, which synchronously orchestrates multiple physiological, cellular, and organ functions[26]. The gut maintains an anti-inflammatory state that supports the growth of trillions of commensal bacteria, which modulate the function of other organs like the brain, heart, kidney, lungs, and liver while favoring its core functions like digestion, absorption of nutrients, and excretion of waste matter[27-30]. This inter-compartmentalized crossstalk infers the need to develop effective gut-specific therapeutics that could limit systemic pathology during diverse viral infections such as human immunodeficiency virus (HIV), SARS-CoV-2, and other related respiratory viruses.

**IMMUNE ARCHITECTURE OF A HEALTHY GUT**

The gut is one of the most complex immune organs containing a wide variety of immune cells, including myeloid cells, conventional T cells, innate lymphoid cells (e.g., natural killer cells and specialized intraepithelial lymphocyte populations), and epithelial cells[31]. Homeostasis in a healthy gut is mainly fostered through the sustenance of an anti-inflammatory environment crucial for maintaining tolerance to oral antigens, commensal microflora, and bridging an intact mucosal barrier[32,33]. Commensal microflora competes with pathobionts (potentially pathogenic bacteria which are benign during homeostasis) for nutrients within the gut microenvironment, secretes toxins that favor their predominance, and release metabolites that shape gut immunity by providing appropriate anti-inflammatory signals to other immune cells such as macrophages[31,34].

Critical genera of the microbiome also ferment dietary fiber into short-chain fatty acids that support gut immune responses by sustaining the balance of T regulatory (T reg) cells and activated T cells[35]. The released short-chain fatty acids such as butyrate facilitate CD103+ dendritic cell production of retinoic acid, which in turn aid in the generation of FoxP3+ T reg cells and sampling of an antigen across the gut lumen. Increased frequencies of CD4+ regulatory T cells maintain a basal anti-inflammatory state of the gut. Released acetate also improves the integrity of gut epithelial cells[36,37]. Additionally, lamina propria macrophages are highly phagocytic and engulf any foreign microorganisms that may have breached the intact gut mucosal barrier[38]. The gut epithelial cells secrete anti-inflammatory cytokines such as interleukin 10 (IL-10) and transforming growth factor-β (TGF-β), which promote increased frequencies of T regs that are crucial for immunological suppression and induction of mucosal tolerance[39-41].

**SARS-COV-2 INFECTION IN THE GUT**

During gut infection, SARS-CoV-2 uses its spike (S) proteins on the virus’s surface to directly bind to the ACE2 receptor that is highly expressed on target intestinal epithelial cells (enterocytes and goblet cells). A transmembrane serine protease (TMPRSS2) acts synergistically and cleaves the S protein into S1 and S2 subunits, facilitating the host cell’s viral entry[15]. Like other viruses such as rotavirus, norovirus, and enteroviruses, the interferon-stimulated genes are activated, resulting in the reinstatement of an antiviral state and restricted SARS-CoV-2 replication[42-44]. Simultaneously, pro-inflammatory cytokines like IL-6, IL-1, and tumor necrosis factor-α (TNF-α) are also released[44]. Severe enterocyte apoptosis follows as soon as the virus overcomes the interferon-mediated antiviral state[16]. The tremendous loss of intestinal epithelial cells diminishes the gut barrier’s integrity and gravely impacts the absorption of nutrients, secretion of mucus, and production of antimicrobial peptides [45]. The elevated secretion of pro-inflammatory cytokines also simultaneously activates macrophages towards pro-inflammatory states, which involves the increased surface expression and later shedding of markers such as CD14 and CD163 that are critical for detecting microorganisms and limiting inflammation[16].
A recent unpublished study that comprehensively investigated changes in gut dynamics during SARS-CoV-2 infection shows that there were increases in permeability of gut tight junctions as estimated using zonulin, microbial translocation, lipid-binding protein, and myeloid activation using soluble CD14[46]. Gut barrier damage, microbial translocation, and myeloid cell activation worsened as the disease transitioned into more severe states. All this was heralded when a two-fold increment in tight junction permeability was observed in individuals who died vs COVID-19 survivors. Unsurprisingly, alterations in gut homeostasis positively correlated with elevated IL-6, thus confirming increased inflammation as a conduit for loss of gut barrier integrity[46]. Lastly, progressive increments of disrupted citrulline metabolism accompanying the severity of SARS-CoV-2 indicate ongoing microbial dysbiosis and impaired intestinal function[47].

GUT INFLAMMATION AND SARS-COV-2

An optimal balance between T regs and inflammatory T helper 17 (Th17) cells is maintained within a healthy gut. As inflammation occurs, this balance is tipped as pro-inflammatory bacteria are favored over commensals[37]. These pro-inflammatory bacteria induce the secretion of cytokines like IL-6 and IL-17 that select for increased frequencies of Th17 pro-inflammatory CD4+ T cells and susceptibility to inflammatory conditions such as inflammatory bowel disease (IBD)[37].

An increased expression of SARS-CoV-2 receptors during other inflammatory conditions has been suggested to affect disease pathogenesis. During IBD and Crohn’s disease (CD), epithelial ACE2 expression is elevated in the colon and rectum while diminished in the ileum[48]. As anticipated, gut dysbiosis occurs as pathobionts outcompete commensal bacteria, and macrophage populations transition towards inflammatory states where they secrete increased amounts of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12[49,50]. The resultant inflammatory damage leads to the destruction of tight junctions within the gut barrier. This later leads to leakage of microbial contents into the systemic circulation. Microbial translocation then ensues and later fuels chronic immune activation[49].

Several studies have investigated the co-occurrence of IBD and COVID-19-related illnesses[51-53]. Here, we discuss the possibility of leveraging IBD therapeutics for treating COVID-19-related symptoms. Current IBD treatments can be divided into two broad categories: (1) Non-biologic; and (2) Biologic therapeutics. Examples of non-biologic therapeutics include small molecules corticosteroids, thiopurines, and 5-aminosalicylates. Each of these therapeutics non-specifically targets multiple inflammatory processes.

On the other hand, biologic therapies target specific inflammatory mediators in the gut to modulate their ability to induce signal transduction[11]. Current biologics used to treat IBD include the monoclonal antibodies infliximab, ustekinumab, and vedolizumab. Infliximab and ustekinumab target pro-inflammatory cytokines TNF-α and IL-12/IL-23, respectively. Since these cytokines are not specific to intestinal inflammation, antibodies that inhibit their action can act throughout the periphery. More specific therapies target IBD like vedolizumab function by blocking the gut homing receptor α4β7 integrin, thereby blocking inflammatory lymphocyte trafficking resulting in reduced inflammation[41,54,55]. Similarly, the biologic natalizumab, an anti-α4 integrin antibody, is also used to treat Crohn’s disease, albeit less frequently due to an increased risk of progressive multifocal leukoencephalopathy (Table 1)[56].

Several studies have suggested that IBD non-biologic therapies may worsen clinical outcomes during COVID-19[57-59]. For example, 5-aminosalicylate and its prodrg form sulfasalazine have increased the risk of SARS-CoV-2 infection and increased the risk of hospitalization and mortality[57-59]. Other immunomodulators include thiopurines, calcineurin inhibitors, and methotrexate. When grouped in meta-analyses, these immunomodulators were also associated with an increased risk of infection, hospitalization, and mortality during SARS-CoV-2 infection[57-59]. The data for corticosteroids is more complicated[57-59]. Owing to their nature as non-selective hormone analogs, corticosteroids target gut inflammation non-specifically, resulting in a dampening of the inflammatory response beyond the intestines. This dampened immune response can therefore inhibit the clearance of replicating virus and prolong the duration of infection. Corticosteroids may further negatively impact clinical outcomes by increasing the pro-thrombotic response to SARS-CoV-2, exacerbating already frequent clotting in intrinsically vascular disease. Several case studies have linked this hypercoagulable state in COVID-19 to worsening in the gut, including
ischemic colitis, potentially aggravating an already disrupted gut homeostasis[60,61]. Therefore, it is unsurprising that studies to determine the impact of IBD therapy on COVID-19 have not been pursued. Nonetheless, corticosteroids for IBD are typically administered long-term and precede SARS-CoV-2 infection. Corticosteroids, particularly dexamethasone, reduce mortality in hospitalized SARS-CoV-2 patients receiving oxygen and reduce intensive care unit hospitalization length when given at moderate doses over a short period (6 mg for up to 10 d)[20,62]. In this context, dexamethasone is typically given after the body has begun clearing the virus but before the worst symptoms of COVID-19 due to cytokine storm arise[63]. The difference in infection rate and clinical outcomes for patients receiving treatment before infection suggests that timing is critical for optimizing corticosteroid use.

In addition to modulating immune responses directly, non-biologic medications may influence COVID-19 pathogenesis in other ways. For instance, people receiving non-biologic medications such as corticosteroids, thiopurines, and 5-aminosalicylates have reduced ACE2 and TMPRSS2 expression on enterocytes in the inflamed colon rectum, but not the ileum[48]. This suggests that despite the adverse clinical outcomes with these medications, they may reduce productive gut epithelial infections in people living with IBD. However, these drugs did not cause changes to receptor expression in the uninflamed gut[48]. In contrast, some biologics used to treat IBD have been mostly, though not exclusively, linked to improved clinical outcomes during SARS-CoV-2 infection, offering novel therapeutic interventions. Early studies have shown that the patients administered biologics did not have an increased risk of COVID-19, despite being considered immunocompromised[64,65]. Individual case studies demonstrate that targeting TNF-α with infliximab promises to improve pulmonary symptoms related to COVID-19[66]. Further, an early study grouping multiple biologic therapies showed that clinical outcomes for individuals taking these biologics were five times less likely to be diagnosed with a SARS-CoV-2 infection[67]. However, this analysis was limited due to the small sample size and inability to separate the specific therapies.

A more recent meta-analysis, again grouping different biologics (anti-TNF-α, ustekinumab, and vedolizumab), demonstrated that their use was associated with a risk ratio of hospitalization 0.34 [95% confidence interval (CI) 0.19-0.61], need for intensive care unit 0.49 [95%CI 0.33-0.72], and mortality 0.22 [95%CI 0.13-0.38], suggesting a substantial improvement in clinical outcome[57]. However, one concern is that because people treated with biologics have such muted symptomology, they may serve as silent carriers of SARS-CoV-2[68]. In addition to reducing symptoms, infliximab has also been shown to reduce the expression of ACE2 in the colon, potentially limiting the productive infection of the gut[48]. Because of these findings, a continued study of these monoclonal antibodies is warranted. Luckily, several clinical trials are currently underway, including anti-TNF-α therapies infliximab and

### Table 1 Comprehensive list of available gut-based and vagus nerve therapies that could be leveraged to limit the severity of coronavirus disease 19 infection

| Therapy | Target | Impact | Clinical outcome |
|---------|--------|--------|------------------|
| Infliximab[57,58] | TNF-α | Reduced pro-inflammatory response induction and leukocyte migration | Reduced infection rate, symptoms, hospital rate, and mortality |
| Ustekinumab[57] | IL-12/IL-23 | Blocks T cell activation | Possible improved outcome (pooled with other biologics) |
| Vedolizumab[54,57] | α4β7 integrin | Reduced leukocyte trafficking to gut and associated inflammation | Possible improved outcome (pooled with other biologics) |
| Corticosteroids[57,58,63] | Glucocorticoid and mineralocorticoid receptors | Reduced inflammatory response | Better or worse clinical outcomes, depending on the timing |
| Microbiome[176] | Butyrate production | Improved gut barrier integrity and decreased microbial translocation | Reduced inflammatory response |
| Vitamin D[70,72,74] | Th17 cells | Reduced gut and systemic inflammation | Reduced infection risk and enhanced clinical outcomes |
| Nicotine and related agonists[142,152,153] | α7nAChR | Reduced Inflammatory Response | Reduced infection rate |
| Vagus nerve stimulation[151] | α7nAChR | Increased acetylcholine release | Reduced inflammation |

TNF-α: Tumor necrosis factor-α; IL: Interleukin; Th17: T helper; nAChR: Nicotinic acetylcholine receptor.
In addition to prescription therapeutics, other recommendations for IBD can also be applied to SARS-CoV-2 infection. COVID-19 pathogenesis has been characterized primarily by dysregulation of the systemic pro-inflammatory response of Th17 cells, particularly during the cytokine storm. This includes decreases in CD4+ T cells expressing Th17 markers CCR6 and CD161, increasing senescence and exhaustion markers CD57 and PD-1[69]. The total number of IL-17A-producing CD4+ and CD8+ T cells was significantly increased despite these findings. These studies suggest that targeting IL-17 may improve clinical outcomes for COVID-19 patients[69].

Further, early during the pandemic, low circulating vitamin D became a known risk factor for SARS-CoV-2 infection, and severe pathogenesis, including associations with significantly higher pro-inflammatory cytokines, including IL-6[70,71] was noted. For this reason, vitamin D supplementation has been recommended for high-risk individuals[70]. Oral vitamin D supplements are absorbed by the small intestine, where they may modulate local Th17 cells, including reduced production of IL-17[72]. In clinical practice, vitamin D is frequently recommended for patients prescribed corticosteroids to manage their IBD symptoms to prevent bone density loss[73]. It is also recommended to reduce or protect against IBD onset of symptoms, in part by suppressing IL-17 production[72]. Further, vitamin D has been linked to increased expression of tight epithelial junctions and blocking apoptosis in the intestine, strengthening gut integrity and preventing bacterial translocation[74,75]. However, whether dampened COVID-19 pathogenesis is linked to inhibition of pro-inflammatory Th17 cells or by a different mechanism remains unknown.

One final concern regarding SARS-CoV-2 during IBD has been the safety and efficacy of vaccination with current therapeutics, many of which are immunosuppressive because so far, phase III clinical trials have excluded patients with IBD[76,77]. Previous studies have found IBD patients treated with anti-TNF-α therapies have a muted response when administered other vaccines (pneumococcal, influenza), leading to further questioning of efficacy[76,78,79]. Despite these concerns, the benefits of vaccination outweigh many of the risks of SARS-CoV-2 infection, and vaccination is likely beneficial for most patients with IBD, even if receiving immunosuppressive therapies[76,80,81]. However, future studies are needed to determine efficacy for this population.

SARS-COV-2 INFECTION RESULTS IN MICROBIAL DYSBIOSIS IN THE GUT

SARS-CoV-2-related microbial dysbiosis manifests the enrichment of pathobionts such as Ruminococcus gravis, Ruminococcus torques, and Bacteroides dorei (B. dorei) Bacteroides vulgatus. These bacteria have also been implicated in IBD and ulcerative colitis pathogenesis, further strengthening their role in gut dysfunction[82,83]. SARS-CoV-2 dysbiosis was also accompanied by loss of crucial bacteria that have been previously implicated in the lowering of inflammation, such as Bifidobacterium adolescentis, Faecalibacterium prausnitzii (F. prausnitzii), Collinsella aerofaciens, and Eubacterium rectale (E. rectale)[84] (Figure 1). Another study highlighted that Clostridium hathewayi (C. hathewayi), Clostridium ramosum (C. ramosum), and Coprobacillus were linked to COVID-19 severity[85]. Unsurprisingly, these microbial signatures (C. hathewayi, C. ramosum, and Coprobacillus) have also been associated with pathogenic/inflammatory gut conditions such as diarrhea, colitis, IBD, and overall inflammation[86-88]. This situation’s gravitas is further supported by observations made in a separate study that showed that the inflammatory species, Proteobacteria, was reported in the guts of COVID-19 patients[89].

Alternatively, several anti-inflammatory bacteria, including F. prausnitzii, B. dorei, Bacteroides thetaiotaomicron, Bacteroides massiliensis, and Bacteroides ovatus were linked to improved clinical outcomes in SARS-CoV-2 patients. Remarkably, Bacteroides were reported to down-regulate ACE2 expression in the gut[85]. The fecal microbiome has also been determined to be dysbiotic for periods as long as 30 d after clearance of SARS-CoV-2 infection, further contributing to the extensive list of health complications reported in COVID long haulers who never wholly recover and recuperate to a healthy state[84,90]. To this effect, it was noted that microbiomes of recovered patients were enriched in Bifidobacterium dentium and Lactobacillus ruminis species and reduced E. rectale, Ruminococcus bromii, F. prausnitzii, and Bifidobacterium longum[84]. Therapeutics involving antibiotics to stabilize the gut microbiome by eliminating SARS-CoV-2 associated pathobionts revealed that these regimens did not affect the
Severe acute respiratory syndrome coronavirus 2 infection induces microbial dysbiosis and intestinal inflammation. Severe acute respiratory syndrome coronavirus 2 infections of intestinal epithelial cells result in a pro-inflammatory immune response leading to infiltration of inflammatory lymphocytes and disrupting the gut barrier. This disruption to homeostasis allows overgrowth of detrimental bacteria resulting in dysbiosis, and the impaired gut barrier facilitates the translocation of bacteria exacerbating the inflammatory response. Additionally, opportunistic fungal infections have been found in some patients, further contributing to the dysfunction. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Recovery of the microbiome. Therefore, these findings negate this approach as a possible future gut microbial rejuvenation strategy[84]. In contrast, previous studies have shown that probiotics improve immune responses to other respiratory tract viral infections such as Influenza and Rhinoviruses[91,92]. Also, in patients with severe COVID-19 disease who cannot ingest probiotics, the use of butyrate enemas could act as adjunctive therapy for repairing intestinal epithelial cell wall damage, lowering chronic immune activation promoting gut-brain axis function[93].

Analysis of the fungal mycobiome using deep shotgun metagenomic sequencing revealed significant proportions of opportunistic fungal pathogens such as Candida albicans, Candida auris, and Aspergillus flavus were enriched in the gut microbiota of COVID-19 hospitalized patients[94]. Similarly, separate studies have detected Aspergillus in respiratory tract secretions and tracheal aspirates of patients with COVID-19[95,96]. Unsurprisingly, in patients with Aspergillus in their fecal microbiomes, the cough was noted as one of the significant symptoms that emphasized intricate systemic distortion of the gut-lung axis[97]. In such cases, antifungal medications should be considered.

THE SARS-COV-2 INFECTION AFFECTS THE HOMEOSTASIS OF THE GUT-LUNG AXIS

The gut-lung axis has been proposed to be a bi-directional conduit by which each organ can modulate the function and inflammatory state. This includes the production of metabolites such as short-chain fatty acids (SCFAs) by the gut microbiome, lymphocyte trafficking from the lungs or the gut into the periphery where they redirect systemic immune responses, and indirect neuronal innervation via the central nervous system (CNS) and cranial nerves bridging each organ[98,99]. The bi-directionality of the gut-lung axis, while capable of promoting beneficial communication, as noted, also represents an avenue for disruption in immune regulation. Changes in the composition and function of the gastrointestinal flora operate to effect change in the respiratory tract through the mucosal immune system, while reciprocally, disturbances to the respiratory tract flora consequently affect the digestive tract through immune regulation[100]. Infection from SARS-CoV-2 causes effector CD4+ T cells to reach the small intestine by accessing the C-C chemokine receptor type 9 (CCR9) via the gut-lung axis resulting in intestinal immune damage and diarrhea[101]. A study related to the influenza virus demonstrated that lung-derived CCR9+CD4+ T cell levels were increased following viral infection[102]. Ye et al [103] summarized that the small intestinal epithelium can express CCL25, which actively recruits CCR9+CD4+ T cells to the small intestine, resulting in intestinal immune damage and polarization of Th17 cells in conjunction with overproduction of
IL-17A. This, in turn, leads to neutrophil recruitment, thus establishing diarrhea onset and other gastrointestinal symptoms during SARS-CoV-2 infection. Generally, COVID-19 patients presenting with gastrointestinal symptoms (> 20% of cases) are more likely to be complicated by acute respiratory distress syndrome (ARDS) and are more prone to fatigue, headache, and cough [101]. Another pathway that may be involved in the severity of ARDS during SARS-CoV-2 infection is the C5a-C5aR1 axis. Proportionate to the severity of ARDS, soluble levels of C5a were found to be increased, and C5aR1 receptors were reported with high expression levels in the blood and pulmonary myeloid cells; furthermore, in C5aR1 knock-in mice, acute lung injury was prevented by the introduction of anti-C5aR1 therapeutic monoclonal antibodies suggesting that this axis could be used to limit lung inflammation [89]. Given that ACE2 is highly expressed in the gastrointestinal tract, specifically intestinal epithelial cells, the esophagus, and the lungs, this may make it a target organ for SARS-CoV-2 infection [102]. Therefore, probiotics offer a favorable potential treatment addressing the gastrointestinal symptoms in COVID-19 by operating to sustain the healthy balance of the gut microecology and protect the respiratory tract from bacterial infections [100]. ACE2, while present across different tissue types, is most prominent in the lungs, which highlights the importance of understanding the network involved to combat the hypersensitivity of the receptor in this tissue, which may lead to worse respiratory illness.

Another branch that extends from the lung-gut axis includes the lung-brain conduit, which proposes to connect severe neurological dysfunction and injury with associated lung injury. In general, CoV-induced inflammation and oxidative stress may represent a crucial mechanism for the onset of neurological symptoms. SARS-CoV-2, in particular, has been shown to have the neuroinvasive potential [104]. The vagus nerve innervates the lung’s distal airway, and upon stimulation, nerve endings release acetylcholine (ACh), which functions to regulate lung infection [105] (Figure 2). ACh secreted from neuronal and non-neuronal sources acts to decrease inflammation, and using an Influenza A model, a previous study showed that viral infection caused an influx of cholinergic lymphocytes while inhibiting ACh synthesis resulted in extended pulmonary inflammation, increased inflammatory macrophage activation, and delayed tissue repair (Reviewed in [106]).

Similarly, it was demonstrated that a deficiency to the α7 nicotinic ACh receptor (nAChR) acts to worsen lung infection, inflammation, and injury while increasing circulatory levels of pro-inflammatory cytokines. Additionally, α7 nAChR activation by GTS-21, which enhances the phagocytic ability of hyperoxic macrophages, is a prominent method for improving bacterial clearance and reducing lung injury [107], suggesting an involvement of lung-gut-brain connection. During infection, viruses may breach the CNS by various routes, including the vasculature, olfactory and trigeminal nerves, or the lymphatic system. However, the direct mechanism that SARS-CoV-2 utilizes is unknown [108]. One hypothesis is that SARS-CoV-2 enters the CNS by breaching the olfactory route, thereby circumventing the blood-brain barrier (BBB). More than 80% of COVID-19 patients presented with gustatory and olfactory impairments lending support to this access point [104].

Furthermore, in a cohort of 214 COVID-19 patients, 36.4% developed neurologic symptoms ranging from acute cerebrovascular diseases, consciousness impairment, and skeletal muscle symptoms [109]. As reviewed by Nuzzo and Picone, another study used a cellular model to demonstrate that respiratory syncytial virus infection propagates reactive oxygen species (ROS) production transitorily, creating oxidative stress that supports the idea that lung inflammation may be a determinant of systemic oxidative stress [104]. The brain, a primary tissue for metabolizing oxygen, is particularly vulnerable to ROS, and SARS-CoV-2 could generate enough ROS to cause brain injury.

In addition to the host immune system’s direct mutual interaction in the gut-brain-lung axis, commensal and pathogenic bacteria in the gut microbiome can also influence COVID-19 pathogenesis. SCFAs such as acetate, butyrate, and propionate, being the most prominent immunomodulatory metabolites, maintain and reinforce intestinal epithelial integrity to decrease inflammation in the gastrointestinal tract and respiratory tract by increasing differentiation and fortifying against tight junction permeability [110]. During SARS-CoV-2 infection, increased permeability was associated with clinical worsening, including multiorgan failure [111]. SCFAs produced by the microbiota influence the inflammatory state of the host’s epithelial cells, innate and adaptive immune cells directly or indirectly, and utilize the mesenteric lymphatic system for translocation of intact bacteria, their fragments or metabolites through the intestinal barrier, thereby modulating the lung immune response upon entry to the systemic circulation [112, 113]. Additionally, SFCA butyrate suppresses intestinal...
inflammation by inhibiting histone deacetylase (HDAC) activity. Inhibition of HDAC enhances the mTOR-S6K pathway required for T cell differentiation and cytokine expression and enhances histone 3 acetylation at Foxp3 Locus to allow transcription to occur and Treg cell differentiation[114,115] Further, GPR43 activation by butyrate can inhibit NF-κB activity and stimulate anti-inflammatory signaling, including IL-8 and IL-10[116].

Previous work on other respiratory viruses also documents disruptions to the gut microbiota. Interestingly, SARS-CoV-2 has been reported to deplete the levels of short-chain fatty acid-producing bacteria such as Parabacteroides merdae, Bacteroides stercoris, and Lachnospiraceae bacterium[117]. Thus, respiratory influenza can indirectly induce intestinal immune injury and alter gut microbiota, resulting in the outgrowth of Enterobacteriaceae and reduction of Lactobacilli and Lactococci[113]. In the influenza-related lung response in mice, intestinal TLR activation is required for NF-κB-dependent pathways for the innate immune response. In this case, disruptions of the microbiota were unrelated to the influenza virus and mediated by Th17 cells[118].

Similarly, other respiratory infections, such as a respiratory syncytial virus (RSV), distort the gut microbiome's balance by depleting Lachnospiraceae and Lactobacillaceae families while enriching Bacteroidaceae[119]. Experimental studies designed to administer high fiber diets favor the enrichment of short-chain fatty acid butyrate-producing bacteria, thus promoting the interferon antiviral state within the lungs of RSV-infected individuals[120]. In turn, depletion of the gut microbiome has been shown to hinder optimal alveolar macrophages' optimal functionality by reducing oxidative respiratory burst capacity and later diminishing their bactericidal effects[121].

**IMPACT OF SARS-COV-2 INFECTION ON THE BRAIN-GUT AXIS**

The gut microbiome has been shown to directly modulate multiple brain functions such as immune modalities like inflammation and neuroendocrine states like mood, stress, anxiety, and memory functions[122-125]. Within the gut, two plexuses comprise the enteric nervous system (ENS): one at the submucosa and the other associated with the muscularis propria. Together, these two plexuses sense the inflammatory and local microbial milieu. The ENS can regulate many aspects of CNS health and behavior through the production of inflammatory mediators, hormones, and direct neuronal innervation of the vagus nerve from the medulla oblongata[126,127]. The release of short-chain fatty acids by gut commensal bacteria improves the BBB's integrity, reduces inflammation signaling in microglia/astrocytes, and enhances neurogenesis within neurons. Collectively, this promotes reduced aging, better memory, and
improved cognitive development[128].

During gut inflammation, as exemplified with IBD, distorted microbiota populations drive mucosal myeloid cells’ activation and subsequent release of pro-inflammatory cytokines that sustain epithelial gut damage. In turn, this activates a cascade of gut pain sensory pathways, dysregulates the enteric nervous system, and simultaneous gut-brain dysfunctions[129-132]. Besides distortion of the lung-gut axis, SARS-CoV-2 dysbiosis of the microbiome could also negatively impact other organs such as the brain. SARS-CoV-2 diminishes crosstalk with the brain by depleting crucial short-chain fatty acid-producing bacteria within the gut microbiome[117] (Figure 3). Furthermore, SARS-CoV-2 has been shown to gain access to the brain by crossing the neural–mucosal interface in olfactory mucosa, where the olfactory mucosal, endothelial, and nervous tissue are closely intertwined[133]. After this, SARS-CoV-2 localizes within the medulla, where respiratory and cardiovascular activities are controlled[133-135]. Thus, this could account for the neurological symptoms such as loss of smell and taste, persistent headaches, confusion, cerebrovascular disease, muscle pain, ataxia, seizures, and dizziness observed in COVID-19 patients[136]. The CNS also supports gut function making the gut-brain axis bi-directional[137,138]. However, the impact of SARS-CoV-2 pathology within the CNS on the direction of gut functions such as peristalsis, modulation of gut immune responses, and directing digestion is yet to be fully comprehended[139].

NICOTINE RECEPTORS, POSSIBLE THERAPEUTIC TARGETS FOR LIMITING SARS-COV-2 DAMAGE IN THE GUT AND BRAIN

Several epidemiological studies from the United States, Europe, and south and east Asia have concluded that tobacco smokers have a lower risk of SARS-CoV-2 infection [140-144]. Additionally, smokers may also have a reduced risk of significant symptoms once infected with SARS-CoV-2, despite typically experiencing increased morbidity and mortality during other respiratory infections[142]. Nicotine is the receptor agonist for nAChRs that contribute to tobacco smoke’s addictive and psychoactive properties. In contrast to exogenous nicotine, the endogenous agonist for nAChRs, ACh is produced by neurons and lymphocytes, an essential neuro-immune modulator. The α7nAChR, in particular, regulates the cholinergic anti-inflammatory response (CAIP) [145]. During acute inflammation, efferent signals from the CNS induce the release of ACh at the enteric nervous system, where they modulate T-cell dynamics, including the induction of Tregs and inhibition of Th17 cells and suppression of local inflammation, including the releases of TNF-α, IL-1β, and HMGB1[146,147]. One hypothesis for nicotine’s inhibitory effects is that exogenous α7nAChR agonists recapitulate the effects of ACh release by the vagus nerve, thereby reducing cytokine storm risk both locally at the inhalation site (the lungs) and systemically, including in the gut. This mechanism may be a likely reason nicotine improves ulcerative colitis symptoms[146,148]. The argument for cholinergic modulation is made even more compelling when considering that neither smoking nor nicotine consumption decreases ACE2 or TMPRSS2 and may increase their expression in the lower airways[149,150]. COVID-19 patients should not be encouraged to smoke or consume nicotine. However, alternative methods of modulating the CAIP have been suggested. Vagus nerve stimulation (VNS) delivers electrical impulses to the left vagus nerve via a small device implanted below the collar bone currently used to treat treatment-resistant epilepsy and major depressive disorder. However, less-invasive transcutaneous auricular VNS is being developed. Although more extensive clinical studies are ongoing, case studies have indicated possible benefits in reducing plasma IL-6 levels when using these devices[151]. Alternatively, α7nAChR agonists or acetylcholinesterase inhibitors have been proposed to reduce systemic inflammation[152,153].

A recent report describing ACE2 and TMPRSS2 expression during chronic vagus nerve stimulation showed no changes in either protein or enterocytes[154], although each gene was strongly correlated with CHRNA7 gene expression RNA-seq[154]. Another report separately described how the spike glycoprotein's receptor-binding domain on SARS-CoV-2 possesses significant structural homology with α-bungarotoxin, a neurotoxin produced by kraits that target α7nAChR, the product of CHRNA7 translation[155]. In their discussion, the authors suggest this homology blocks normal cholinergic signaling by competitive inhibition leading to an excessive pro-inflammatory response that cannot be alleviated by vagal signaling. If that is the case, the co-expression of CHRNA7 and ACE2 with TMPRSS2 would mean that infected gut epithelial cells are producing viral particles that inhibit cholinergic
Figure 3 Potential mechanisms by which severe acute respiratory syndrome coronavirus 2 dysregulates the gut-brain axis. Side by side comparisons of the gut-brain-lung axis in a healthy state vs a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposed state. In a healthy state, commensal bacteria outcompete pathogens within the gut micro-environment leading to a predominantly anti-inflammatory state. Peptides released by commensal gut bacteria support optimal brain and lung function. During SARS-CoV-2 infection, gut microbial dysbiosis dysregulates gut, lung, and brain function. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; BBB: Blood-brain barrier; AM: Alveolar macrophages; SCFA: Short-chain fatty acids; T-regs: T regulatory cells. 

It should be noted that in addition to a disruption to its anti-inflammatory functions, the vagus nerve may also contribute to the COVID-19 pathology in other ways. During Parkinson’s disease, α-synuclein aggregates travel from the gut to the CNS in the vagus nerve via retrograde axonal transport[158]. The innervation of both the lungs and gut, where significant viral replication occurs, may allow a similar direct transport to the CNS[159]. This hypothesis is corroborated by the recent reports, which showed that the brain stem has an increased inflammatory response during COVID-19 compared with other brain regions. Where cranial nerves IX and X (glossopharyngeal and vagus nerves) meet, the medulla oblongata, in particular, has a higher viral load than the rest of the CNS[160]. The axonal and synaptic loss at the dorsal motor nucleus and nucleus solitarius near this region may be contributing to the loss of autonomic control of respiratory function, cardiac arrhythmias, and gastrointestinal symptoms like diarrhea and vomiting[161,162]. Complicating the role of nicotine in COVID-19 pathogenesis, its administration can inhibit Th17-driven neuroinflammation, thereby possibly protecting these regions in smokers[163]. A better understanding of this process, if it exists, could contribute significantly to minimizing neuropathogenesis during SARS-CoV-2 infection.

CONCLUSION

SARS-CoV-2 infection in the gut leads to alterations in gut microbiota with depletion of bacterial genera that produce crucial metabolites such as short-chain fatty acids that sustain optimal brain function. Future studies focusing on using probiotics to replenish commensals’ dwindling populations as a strategy to reverse gut dysbiosis while maintaining the gut-brain axis during COVID-19 are needed[164]. Furthermore, additional efforts should be applied to the testing strategies currently used to manage inflammatory conditions affecting the gut for their potential in the direction of signaling on themselves. A loss of cholinergic signaling fails to block HMGB1, allowing increased microbial translocation at the gut barrier exacerbating inflammatory responses[156]. Targeting this interaction on colonocytes may offer considerable protection from pathogenesis, including the cytokine storm. A similar correlation between ACE2 and CHRNA7 expression has been found on airway epithelial cells, suggesting these cells specifically may be the mechanism by which nicotine modulates infection rates and pathogenesis when endogenous ACh fails[157].
Elevated baseline gut inflammation observed in Sub-Saharan African individuals could lead to severe coronavirus disease 19 associated dysregulation of the gut-brain-lung axis. Continuous exposure to various endemic pathogens such as human immunodeficiency virus, tuberculosis, multiple vectors like tsetse flies, and several mosquitoes, in addition to low diets, set the ground for high levels of gut dysbiosis within the entire community populations. Additional studies focused on evaluating the effects of baseline gut dysbiosis on coronavirus disease 19 infection are highly warranted.

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; COVID-19: Coronavirus disease 19; HIV: Human immunodeficiency virus; TB: Tuberculosis.

COVID-19 associated dysbiosis, gut damage, and microbial translocation. Targeting vagal stimulation and diverse nicotinic receptors could offer lower organ inflammation and confer systemic protection across the gut-brain and lung organs.

Lastly, special consideration should be given to populations worldwide where there is a high incidence of coinfections such as HIV and tuberculosis (TB) that target the gut early on in infection, cause dysbiosis and lead to microbial translocation[165-167]. In the world’s poorest regions like Sub-Saharan Africa, most individuals are continuously exposed to endemic pathogens like helminths and TB that could lead to elevated baseline levels of gut damage, immune activation, and possible microbial translocation [168-171]. Recently, Bhaskaran et al[172] analyzed data from 27480 individuals co-infected with HIV within the United Kingdom. Their data revealed that people living with HIV had a higher risk of COVID-19 death than those without HIV, after adjusting for the age and sex with a hazard ratio (HR) of 290 (95%CI 0.196-0.430; P < 0.0001). However, the absence of testing, limited case reporting, and poor health care limits our understanding of the SARS-CoV-2 pandemic on this continent[172].

The sudden lifestyle changes imparted by the pandemic within these populations have tremendously strained their chances of survival. In countries where restrictions or lockdowns are enforced, most individuals from these regions rely on the government to supply free food rations[173]. However, the low quality of this freely distributed food fuels the already highly prevalent risk of malnutrition within these populations[174]. As we have illustrated, limited dietary access within these communities could further aggravate gut dysbiosis leading to severe systemic disorientation during SARS-CoV-2 infection. The complexity of these variables, in addition to limited health service delivery and governmental support[175] could exacerbate gut-brain disruptions within diverse populations in Sub-Saharan Africa (Figure 4).

In these trying times of the COVID-19 pandemic, the connotation of a healthy gut-healthy mind could translate into one’s ability to orchestrate a meaningful immune response that could limit SARS-CoV-2 infection and maintain systemic homeostasis and diminish side effects from virus exposure. Leveraging therapies currently being used to improve gut health could be exploited for better disease outcomes during severe disease. Additional studies on the gut-brain axis, particularly from diverse populations across the world, are warranted.
REFERENCES

1 Unwin HJT, Mishra S, Bradley VC, Gandy A, Mellan TA, Coupland H, Ish-Horowicz J, Vollmer MAC, Whitaker C, Filipeli SL, Xi X, Monod M, Ratmann O, Hutchinson M, Valka F, Zhu H, Hawryluk I, Milton P, Amslie KEC, Baguelin M, Boonyasiri A, Brazeau NF, Cattarino L, Cucunubá Z, Cuomo-Dannenburg G, Dorigatti I, Eales OD, Eaton JW, van Elsland SL, FitzJohn RG, Gaythorpe KAM, Green W, Hinley W, Jeffrey B, Knock E, Laydon DJ, Les J, Nedjati-Gilani G, Nouvellet P, Ockell L, Parag KV, Siveroni I, Thompson HA, Walker P, Walters CE, Watson OJ, Whittles LK, Ghani AC, Ferguson NM, Riley S, Donnelly CA, Bhattacharya S, Flaxman S. State-level tracking of COVID-19 in the United States. Nat Commun 2020; 11: 6189 [PMID: 33273462 DOI: 10.1038/s41467-020-19652-6]

2 Carvalho VM, Hansen S, Ortiz A, Garcia JR, Rodrigo T, Rodriguez Mora S, Ruiz de Aguirre P. Tracking the COVID-19 crisis with high-resolution transaction data. 2020 April 16 [cited Feb 1, 2021]. In: BBVA Research [Internet]. Available from: https://www.bbbaresearch.com/en/publicaciones/tracking-the-covid-19-crisis-with-high-resolution-transaction-data/

3 Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, Ganesh S, Varsavsky T, Cardoso MJ, El-Sayed Moustafa JS, Visconti A, Hysi P, Bowyer RCE, Mangino M, Falchi M, Wolf J, Ourselin S, Chan AT, Stevens CJ, Spector TD. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med 2020; 26: 1037-1040 [PMID: 32393804 DOI: 10.1038/s41591-020-0916-2]

4 Chong YY, Cheng HY, Chan HYL, Chien WT, Wong SYS. COVID-19 pandemic, infodemic and the role of eHealth literacy. Int J Nurs Stud 2020; 108: 103644 [PMID: 32474127 DOI: 10.1016/j.ijnurstu.2020.103644]

5 COVID Data Tracker. [cited July 15, 2021]. In: Centers for Disease Control and Prevention (CDC) [Internet]. Available from: https://covid.cdc.gov/covid-data-tracker/#/dataTracker-home

6 2020 Global Nutrition Report. 2020 [cited Feb 1, 2021]. In: United Nations International Children’s Emergency Fund (UNICEF) [Internet]. Available from: https://globalnutritionreport.org/reports/2020-global-nutrition-report/

7 Belanger MJ, Hill MA, Angelidi AM, Dalamaga M, Sowers JR, Mantzoros CS. Covid-19 and Disparities in Nutrition and Obesity. N Engl J Med 2020; 383: e69 [PMID: 32668105 DOI: 10.1056/NEJMp21021264]

8 WHO Coronavirus (COVID-19) Dashboard. [cited July 15, 2021]. In: World Health Organization [Internet]. Available from: https://covid19.who.int

9 Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nature Rev Microbiol 2020 [DOI: 10.1038/s41579-020-00459-7]

10 Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433 [PMID: 32113704 DOI: 10.1016/j.jaut.2020.102433]

11 Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol 2020; 35: 744-748 [PMID: 32215956 DOI: 10.1111/jgh.15047]

12 Li L, Jiang X, Zhang Z, Huang S, Fan Z, Gu Z, Gao L, Shi H, Mai L, Liu Y, Lin X, Lai R, Yan Z, Li X, Shan H. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020; 69: 997-1001 [PMID: 32241899 DOI: 10.1136/gutjnl-2020-312103]

13 Zhang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, Liu Z, Brulois KF, Wang X, Greenberg HB, Diamond MS, Ciorda MA, Whelan SP1, Ding S. TMPRSS2 and Tmprss2 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol 2020; 5 [PMID: 32404436 DOI: 10.1126/sciimmunol.abc3582]

14 Segal JP, Mak JWY, Mullish BH, Alexander JL, Ng SC, Marchesi JR. The gut microbiome: an under-recognised contributor to the COVID-19 pandemic? Therap Adv Gastroenterol 2020; 13: 1756284820974914 [PMID: 33281941 DOI: 10.1177/1756284820974914]

15 Xiao F, Tang M, Zeng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 2020; 158: 1831-1833.e3 [PMID: 32142773 DOI: 10.1053/j.gastro.2020.02.055]

16 Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschkof J, Breugem TI, Raveli RBG, Paul van Schayck J, Mykytyn AZ, Duimel HQ, van Donselaar E, Kieseboch S, Kuijpers HH, Schipper D, van de Wetering WJ, de Graaf M, Koopmans M, Cuppen E, Peters PJ, Haagmans BL, Clevers H. SARS-CoV-2 productively infects human gut enterocytes. Science 2020; 369: 50-54 [PMID: 32358202 DOI: 10.1126/science.abc1669]

17 Lee JJ, Kopetz S, Vilar E, Shen JP, Chen K, Maitra A. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. Genes (Basel) 2020; 11 [PMID: 32545271 DOI: 10.3390/genes11060645]

18 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20: 533-543 [PMID: 32087114 DOI: 10.1016/S1473-3099(20)30120-1]

19 Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Translation Res 2020 [DOI: 10.1016/j.trsl.2020.08.004]

20 Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol 2020; 115: 766-773 [PMID: 32287140 DOI: 10.14309/ajg.0000000000000620]
Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 2020; 181: 1036-1045.e9 [PMID: 32416070 DOI: 10.1016/j.cell.2020.04.026]

Patankar JV, Becker C. Cell death in the gut epithelium and implications for chronic inflammation. *Nat Rev Gastroenterol Hepatol* 2020; 17: 543-556 [PMID: 32651553 DOI: 10.1038/s41575-020-0326-4]

Giron LB, Dweep H, Yin X, Wang H, Danma R, Goldman AR, Gorman N, Palmer CS, Tang HY, Shaikh MW, Forsyth CB, Bailey RA, Zilberstein NF, Liu Q, Kossenkov A, Keshavarzian A, Landry MJ, Abdel-Mohsen M. Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients. *Front Immunol* 2021; 12: 686240 [PMID: 34177935 DOI: 10.3389/fimmu.2021.686240]

Kao CC, Cope JL, Hsu JW, Dwarkanath P, Karnes JM, Luna RA, Hollister EB, Thame MM, Kuppad AV, Jahoor F. The Microbiome, Intestinal Function, and Arginine Metabolism of Healthy Indian Women Are Different from Those of American and Jamaican Women. *J Nutr* 2015; 146: 706-713 [PMID: 26962180 DOI: 10.3945/jn.115.227579]

Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Liviano A, Jha D, Levescot A, Irizar H, Kosoy R, Cording S, Wang W, Losic B, Ungaro RC, DiNarzo A, Martínez-Delgado G, Suprun M, Corley MJ, Stojsimovic A, Houten SM, Peters L, Curran M, Brodmerek C, Perrigoue J, Friedman JR, Hao K, Schadt EE, Zhu J, Ko HM, Cho J, Dubinsky MC, Sands BE, Nihlovu L, Cefri-Bensusan N, Kasarskis A, Colombel JF, Harpaz N, Argmann C, Mehandru S. Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. *Gastroenterology* 2021; 160: 287-301.e20 [PMID: 32980345 DOI: 10.1053/j.gastro.2020.09.029]

Vrakas S, Mountzouris KC, Michalopoulos G, Karamanolis G, Papapedeonidis G, Tzathas C, Gazouli M. Intestinal Bacteria Composition and Translocation of Bacteria in Infectious Bowel Disease. *PLoS One* 2017; 12: e0170034 DOI: 10.1371/journal.pone.0170034

Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. *Nat Rev Gastroenterol Hepatol* 2019; 16: 531-543 [PMID: 31201424 DOI: 10.1038/s41575-019-0172-4]

Neurath MF. COVID-19 and immunomodulation in IBD. *Gut* 2020; 69: 1335-1342 [PMID: 32303609 DOI: 10.1136/gutjnl-2020-321269]

Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, Goyal H. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. *Ann Gastroenterol* 2020; 33: 591-602 [PMID: 33162736 DOI: 10.20524/aog.2020.0547]

Jablouzi A, Kriaa A, Mkaouar H, Akermi N, Soussou S, Wysocka M, Mekhalif M, Fecal Serine Protease Profiling in Inflammatory Bowel Diseases. *Front Cell Infect Microbiol* 2020; 10: 21 DOI: 10.3389/fcimb.2020.00021

Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. *Clin Pharmacol Ther* 2015; 97: 22-28 [PMID: 25670380 DOI: 10.1002/cpt.6]

Athos J, Cicala C, Nawaz F, Byrareddy SN, Villinger F, Santangelo PJ, Ansari AA, Fauci AS. The Role of Integrin α4β7 in HIV Pathogenesis and Treatment. *Curr HIV/AIDS Rep* 2018; 15: 127-135 DOI: 10.1007/s11904-018-0382-3

Armuzzi A, Felice C. Natalizumab in Crohn's disease: past and future areas of applicability. *Ann Gastroenterol* 2013; 26: 189-190 [PMID: 24714373]

Singh AK, Jena A, Kumar-M P, Sharma V, Sebastian S. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. *United European Gastroenterol J* 2021; 9: 159-176 [PMID: 33210980 DOI: 10.1177/205064620972602]

Brenner EJ, Ungaro RC, Geary RB, Kaplan GG, Kissou-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruenmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology* 2020; 159: 481-491.e483 [DOI: 10.1053/j.gastro.2020.05.032]

Ungaro RC, Brenner EJ, Geary RB, Kaplan GG, Kissou-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. *Gut* 2021; 70: 725-732 [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322339]

Chan KH, Lim SL, Danati A, Maruboyina SP, Bondili L, Abu Hanoud A, Slim J. Coronavirus disease 2019 (COVID-19) and ischemic colitis: an under-recognized complication. *Ann Emerg Med* 2020; 38: 2758.e1-2758.e4 [PMID: 32499176 DOI: 10.1016/j.ajem.2020.05.072]

González Lázaro P, Lomas Meneses A, Del Val Zaballos F, Morandeira Rivas A. Ischemic colitis and short bowel disease due to coronavirus disease 2019 (COVID-19). *Clin Nutr ESPEN* 2020; 40: 406-407 [PMID: 33183570 DOI: 10.1016/j.clnesp.2020.08.009]

RECOVERY Collaborative Group, , Horby P, Lim WS, Emberson JR, Mathaf M, Bell JL, Linsell L, Staplin N, Brightling C, Usianowinski A, Elmhadi E, Prudon B, Green C, Felton T, Chadwick D, Dege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021; 384: 693-704 [PMID: 32678530 DOI: 10.1056/NEJMoa2021436]

Matthy MA, Thompson BT. Dexamethasone in hospitalised patients with COVID-19: addressing...
uncertainties. *Lancet Respir Med* 2020; 8: 1170-1172 [PMID: 33129421 DOI: 10.1016/S2213-2600(20)30503-5]

64 Azir M, Fatima R, Haghbin H, Lee-Smith W, Nawras A. The Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis. *Inflamm Bowel Dis* 2020; 26: e132-e133 [PMID: 32619003 DOI: 10.1093/ibd/izaa170]

65 Marafini I, Salvatori S, Sena G, Calabrese E, Biancone L, Monteleone G. Low frequency of COVID-19 in inflammatory bowel diseases. *Dig Liver Dis* 2020; 52: 1234-1235 [PMID: 32601036 DOI: 10.1016/j.dld.2020.06.007]

66 Bezzio C, Manes G, Bini F, Pellegrini L, Saibeni S. Inflinxisab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. *Gut* 2021; 70: 623-624 [PMID: 32554621 DOI: 10.1136/gutjnl-2020-321760]

67 Bezzio C, Pellegrini L, Manes G, Arena I, Picascia D, Della Corte C, Devani M, Schettino M, Saibeni S. Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2020; 26: e107-e109 [PMID: 32869831 DOI: 10.1093/ibd/izaa242]

68 Baradaran Ghavami SH, Shahrokh SH, Hossein-Khanmazer N, Shpichka A, Asadzadeh Aghdaei H, Timashov P, Vosough M. IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less Prone to its Severe Adverse Events: True or False? *Cell J* 2020; 12: 151-154 [PMID: 32779446 DOI: 10.22074/cellj.2020.7603]

69 De Biasi S, Meschiarì M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Gozzi L, Iannone A, Lo Tartaro D, Mattioli M, Paolini A, Menozzi M, Milì M, Franceschi G, Fantini R, Tonelli R, Sita M, Sarti M, Trenti T, Brugioni L, Cicchetti L, Facchinetti F, Pietrangelo A, Cline E, Girardis M, Guaraldi G, Mussini C, Cossarizza A. Marked CD4+ T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. *Nat Commun* 2020; 11: 3434 [PMID: 32632085 DOI: 10.1038/s41467-020-17792-4]

70 Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. *Sci Rep* 2020; 10: 20191 [PMID: 32314648 DOI: 10.1038/s41598-020-77093-z]

71 Grant WB, Lahore H, McDonnell SL, Baggery CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients* 2020; 12 [PMID: 32252338 DOI: 10.3390/nu12040988]

72 Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. *J Biol Chem* 2010; 285: 38751-38755 [PMID: 20974859 DOI: 10.1074/jbc.C110.185777]

73 Fletcher J, Cooper SC, Ghisho S, Hewison M. The Role of Vitamin D in Inflammatory Bowel Disease: Mechanism to Management. *Nutrients* 2019; 11 [PMID: 31067701 DOI: 10.3390/nu11051019]

74 Lee C, Lau E, Chusilp S, Filler R, Li B, Zhu H, Yamoto M, Pierro A. Protective effects of vitamin D against injury in intestinal epithelium. *Pediatr Surg Int* 2019; 35: 1395-1401 [PMID: 31612340 DOI: 10.1007/s00383-019-05596-y]

75 He L, Liu T, Shi Y, Tian F, Hu H, Deb DK, Chen Y, Bissomatte M, Li Y. Gut Epithelial Vitamin D Receptor Regulates Microbiota-Dependent Mucosal Inflammation by Suppressing Intestinal Epithelial Cell Apoptosis. *Endocrinology* 2018; 159: 967-979 [PMID: 29228157 DOI: 10.1210/en.2017-00748]

76 D’Amico F, Rabaud C, Peyrin-Biroulet L, Danese S. SARS-CoV-2 vaccination in IBD: more pros than cons. *Nat Rev Gastroenterol Hepatol* 2021; 18: 211-213 [PMID: 33473718 DOI: 10.1038/s41575-021-00420-w]

77 Polack FP, Thomas SJ, Kitchin N, Abascal J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Únal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jensen KU, Gruber WC. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; 383: 2603-2615 [DOI: 10.1056/NEJMoa2034577]

78 Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabó H, Sociale OR, Vetrano S, Gurtman A, Perez JL, Perez Marc G, Rabaud C, Peyrin-Biroulet L, Danese S. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. *Inflamm Bowel Dis* 2012; 18: 1042-1047 [PMID: 21674732 DOI: 10.1002/ibd.21800]

79 Manula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007; 5: 851-856 [PMID: 17544875 DOI: 10.1016/j.cgh.2007.02.035]

80 Siegal CD, Melmed GY, McGovern DPB, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. *Gut* 2021; 70: 635-640 [DOI: 10.1136/gutjnl-2020-324000]

81 Alexander JL, Moran GW, Gayà DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J, Segal JP, Sebastian S, Sel linger CP, Parkes M, Smith PJ, Dhar A, Subramanian S, Arasaradnam R, Lamb CA, Ahmad T, Lees CW, Dobson L, Wakeman R, Iqbal TH, Arnott I, Powell N. Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. *Lancet Gastroenterol Hepatol* 2021; 6:
Johnson SD et al. SARS-CoV-2 gut-brain-lung dysregulation

218-224 [PMID: 33508241 DOI: 10.1016/S2468-1253(21)00024-8]

Matsuoka K, Kanaa T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol 2015; 37: 47-55 [PMID: 25420450 DOI: 10.1007/s00281-014-0445-4]

Henke MT, Kenny DJ, Cassilidy CD, Vlamakis H, Xavier RJ, Clardy J. Ruminooccus gnavus, a member of the human gut microbiome associated with Crohn's disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci USA 2019; 116: 12672-12677 [PMID: 31182571 DOI: 10.1073/pnas.1904099116]

Yoooh VK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joyn G, Hui DS-C, Chow KM, Ng SS, Li TC-M, Ng RW, Yip TC, Wong GL-H, Chan FK, Wong CK, Chan PK, Ng SC. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021; 70: 698-706 [DOI: 10.1136/gutjnl-2020-332020]

Zuo T, Zhang F, Lui GCY, Yoooh VK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joyn G, Hui DSC, Chan FKL, Chan PKS, Ng SC. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology 2020; 159: 944-955.e8 [PMID: 32442562 DOI: 10.1053/j.gastro.2020.05.048]

Manzaor SE, McNulty CAM, Nakiboneka-Ssenabulya D, Lecky DJ, Hardy KJ, Hawkey PM. Investigation of community carriage rates of Clostridium difficile and Hungatella hathewayi in healthy volunteers from four regions of England. J Hosp Infect 2017; 97: 153-155 [PMID: 28549779 DOI: 10.1016/j.jhin.2017.05.014]

Du Z, Hudacovic T, Mrazek J, Kozakova H, Srutkova D, Schwarzer M, Tlaskalova-Hogenova H, Kostovcik M, Kverka M. Development of gut inflammation in mice colonized with mucosa-associated bacteria from patients with ulcerative colitis. Gut Pathog 2015; 7: 32 [PMID: 26697117 DOI: 10.1186/s13099-015-0080-2]

Nishino K, Imaeda H, Sakai S, Ohno M, Nishida A, Andoh A. The Abundance of Clostridium hathewayi, a Potent Inducer of T Helper 17 (Th17) Cells, is Associated with the Disease Severity of Crohn's Disease. Gastroenterology 2017; 152: S993

Carvelli J, Demaria O, Velé F, Batista L, Chouaki Bennmansour N, Fares J, Carpenter S, Thibult ML, Morel A, Remark R, André P, Represa A, Pipieroglou C; Explore COVID-19 IPH group; Explore COVID-19 Marseille Immunopole group, Cordier PY, Le Dault E, Guervilly C, Simeone P, Gannier M, Morel Y, Ebbo M, Schleinitz N, Vivier E. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature 2020; 588: 146-150 [PMID: 32726800 DOI: 10.1038/s41586-020-2600-6]

Marshall M. The lasting misery of coronavirus long-haulers. Nature 2020; 585: 339-341 [PMID: 32929257 DOI: 10.1038/d41586-020-02598-6]

Zelaya H, Alvarez S, Kitazawa H, Villena J. Respiratory Antiviral Immunity and Immunobiotics: Beneficial Effects on Inflammation-Coagulation Interaction during Influenza Virus Infection. Front Immunol 2016; 7: 633 [PMID: 28066442 DOI: 10.3389/fimmu.2016.00633]

Turner RB, Woodfolk JA, Borish L, Steinke JW, Patrie JT, Muehling LM, Lahtinen S, Lehtinen MJ. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection - a randomised controlled trial. Benef Microbes 2017; 8: 207-215 [PMID: 28343401 DOI: 10.3920/BM2016.0160]

Archer DL, Kramer DC. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With SARS-CoV-2 Infection. Front Med (Lausanne) 2020; 7: 292 [PMID: 32582742 DOI: 10.3389/fmed.2020.00292]

Zuo T, Zhan H, Zhang F, Liu Q, Tso EYK, Lui GCY, Chen N, Li A, Lu W, Chan FKL, Chan PKS, Ng SC. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. Gastroenterology 2020; 159: 1302-1310.e5 [PMID: 32598884 DOI: 10.1053/j.gastro.2020.06.048]

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8: 475-481 [PMID: 32105632 DOI: 10.1016/S2213-2600(20)30079-5]

Leserc France LX, Boudaoua L, Nguyen D, Parissey M, Wicky PF, Behilli S, Gaynard A, Boucambert-Duchanp M, Donati F, Le Hingrat Q, Enouf V, Houhou-Fidouh N, Valette M, Maitles A, Lucet JC, Mesfret F, Duval X, Descamps D, Malvy D, Timsit JF, Lina B, Vanel-Der-Verf S, Yazdanpanah Y. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020; 20: 697-706 [PMID: 32224310 DOI: 10.1016/S1473-3099(20)30290-0]

 Baba R, Takaoaka H, Kamo T, Arai D, Takahashi H, Masaki K, Shinoda Y, Hayagiwa S, Fukunaga K, Nakachi I. Clinical interpretations and therapeutic significance of isolating aspergillus species from respiratory specimens. Am J Respir Crit Care Med 2020; 201: A2117 [DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2117]

Budden KF, Gellaty SL, Wood DL, Cooper MA, Morrison M, Hugenholz P, Hansbro PM. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15: 55-63 [PMID: 27694885 DOI: 10.1038/nrmicro.2016.142]

Maugnoli LJ, Xu DZ, Lu Q, Deitch EA. Gut-derived mesenteric lymph: a link between burn and lung injury. Arch Surg 1999; 134: 1333-1341 [PMID: 10593331 DOI: 10.1001/archsurg.134.12.1333]

Ahlawat S, Asha, Sharma KK. Immunological co-ordination between gut and lungs in SARS-CoV-2
Johnson SD et al. SARS-CoV-2 gut-brain-lung dysregulation

infection. *Virus Res* 2020; 286: 198103 [PMID: 32717345 DOI: 10.1016/j.virusres.2020.198103]

Ye Q, Wang B, Zhang T, Xu J, Shang S. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. *Am J Physiol Gastrointest Liver Physiol* 2020; 319: G245-G252 [PMID: 32639848 DOI: 10.1152/ajpgi.00148.2020]

Wang J, Li F, Wei H, Lian ZX, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. *J Exp Med* 2014; 211: 2397-2410 [PMID: 25366965 DOI: 10.1084/jem.20140625]

Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Focal-Oral Transmission. *Gastroenterology* 2019; 158: 1518-1519 [PMID: 32142785 DOI: 10.1053/j.gastro.2020.02.054]

Nuzzo D, Picone P. Potential neurological effects of severe COVID-19 infection. *Neurosci Res* 2020; 158: 1-5 [PMID: 32628969 DOI: 10.1016/j.neures.2020.06.009]

Huang Y, Zhao C, Su X. Neuroimmune regulation of lung infection and inflammation. *JIM* 2019; 112: 483-487 [PMID: 30016504 DOI: 10.1093/qimn/qcy154]

Horkowitz AP, Schwartz AV, Alvarez CA, Herrera EB, Thomas ML, Chatfield DA, Osborn KG, Feuer R, George UZ, Phillips JA. Acetylcholine Regulates Pulmonary Pathology During Viral Infection and Recovery. *Immunotargets Ther* 2020; 9: 333-350 [PMID: 33365281 DOI: 10.2147/ITT.S279228]

Sitapara RA, Antoine DJ, Sharma L, Patel VS, Ashby CR Jr, Gorasiya S, Yang H, Zur M, Mantell LL. The α7 nicotinic acetylcholine receptor agonist GTS-21 improves bacterial clearance in mice by restoring hyperoxia-compromised macrophage function. *Mol Med* 2014; 20: 238-247 [PMID: 24664237 DOI: 10.2119/mnmol.2013.00856]

Desforges M, Le Coupanec A, Dubeau P, Bourguinon A, Lajosie L, Dubé M, Talbot PJ. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? *Viruses* 2019; 12 [PMID: 31861926 DOI: 10.3390/v12010014]

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Mao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* 2020; 77: 683-690 [PMID: 32775288 DOI: 10.1001/jamaneurol.2020.1127]

Chen T, Long W, Zhang C, Liu S, Zhao L, Hamaker BR. Fiber-utilizing capacity varies in Prevotella- vs Bacteroides-dominated gut microbiota. *Sci Rep* 2017; 7: 2594 [PMID: 28572676 DOI: 10.1038/s41598-017-02995-4]

Uzzan M, Corcos O, Martin JC, Treton X, Bouhnik Y. Why is SARS-CoV-2 infection more severe in obese men? *Med Hypotheses* 2020; 144: 110023 [PMID: 32593832 DOI: 10.1016/j.mehy.2020.110023]

Bingula R, Filaire M, Radosevic-Robin N, Bey M, Berthon Y, Bernalier-Donadille A, Vasson MP, Filaire E. Desired Turbulence? *Immunotargets Ther* 2020; 10.1093/qjmed/hcy154 [PMID: 31861926 DOI: 10.1093/qjmed/hcy154]

Dang AT, Marsland BJ. Microbes, metabolites, and the gut-lung axis. *Mucosal Immunol* 2019; 12: 843-850 [PMID: 30976087 DOI: 10.1038/s41385-019-0160-6]

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, Glickman JN, Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* 2013; 341: 569-573 [PMID: 23828891 DOI: 10.1126/science.1241165]

Husain A, Byrareddy SN. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. *Chem Biol Interact* 2020; 331: 109282 [PMID: 33031791 DOI: 10.1016/j.cbii.2020.109282]

Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B, Pei G. Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. *Mol Cell* 2004; 14: 303-317 [PMID: 15125834 DOI: 10.1016/s1097-2765(04)00216-3]

Zuo T, Liu Q, Zhang F, Lui GC, Tso EY, Yeoh YK, Chen Z, Boon SS, Chan FK, Chan PK, Ng SC. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. *Gut* 2021; 70: 276-284 [PMID: 32690600 DOI: 10.1136/gutjnl-2020-322294]

Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, Murray TS, Iwasaki A. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci USA* 2011; 108: 5354-5359 [PMID: 21402903 DOI: 10.1073/pnas.1019378108]

Groves HT, Higham SL, Moffatt MF, Cox MJ, Tregonas JS. Respiratory Viral Infection Alters the Gut Microbiota by Inducing Innaptence. *mBio* 2020; 11 [PMID: 32071269 DOI: 10.1128/mBio.03236-19]

Antunes KH, Fichi JL, de Paula R, da Silva EF, Pral LP, Dos Santos AA, Dias GBM, Vargas JE, Puga R, Mayer FQ, Maito F, Zárate-Bladés CR, Ajarni NJ, Sant’Ana MR, Candrevia T, Rodrigues HG, Schmiele M, Silva Clerici MTP, Preenova-Modena JL, Vieira AT, Mackay CR, Mansur D, Caballero MT, Marzee J, Li J, Wang X, Bell D, Polack FP, Kleeberger SR, Stein RT, Vinolo MAR, de Souza APD. Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response. *Nat Commun* 2019; 10: 3273 [PMID: 31332169 DOI: 10.1038/s41467-019-11152-6]

Clarke TB. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. *Infect Immun* 2014; 82: 4596-4606 [PMID: 25135683 DOI: 10.1128/IAI.02212-14]
Liu L, Zha G. Gut-Brain Axis and Mood Disorder. Front Psychiatry 2018; 9: 223 [PMID: 29896129 DOI: 10.3389/fpsyg.2018.00223]

Bioque M, González-Rodríguez A, García-Rizo C, Cobo J, Monreal JA, Usall J, Soria V; PNECAT Group, Labad J. Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: A narrative review. Prog Neuropsychopharmacol Biol Psychiatry 2021; 105: 110130 [PMID: 33945322 DOI: 10.1016/j.pnpbp.2020.110130]

Sanmarco LM, Wheeler MA, Gutiérrez-Vázquez C, Polonios CM, Limmerbauer M, Pinho-Ribeiro FA; Li Z, Giovannoni F, Batterman KV, Scalsi G, Zandee SEJ, Heck ES, Alsawalm M, Rosene DL, Becher B, Chiu DM, Prat A, Quintana FJ. Gut-licensed IFNγ+ NK cells drive LAMPI "TRAIL" anti-inflammatory astrocytes. Nature 2021; 590: 473-479 [DOI: 10.1038/s41586-020-03116-4]

Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 2004; 558: 263-275 [PMID: 15133062 DOI: 10.1113/jphysiol.2004.063388]

Spencer NJ, Hu H. Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility. Nat Rev Gastroenterol Hepatol 2020; 17: 338-351 [PMID: 32152479 DOI: 10.1038/s41575-020-0271-2]

Sharkey KA, Beck PL, McKay DM. Neuroimmunophysiology of the gut: advances and emerging concepts focusing on the epithelium. Nat Rev Gastroenterol Hepatol 2018; 15: 765-784 [PMID: 30069036 DOI: 10.1038/s41575-018-0051-4]

Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication. Front Endocrinol (Lassanne) 2020; 11: 25 [PMID: 32082260 DOI: 10.3389/fendo.2020.00025]

Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500-1512 [PMID: 24583088 DOI: 10.1053/j.gastro.2014.02.037]

Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 2014; 39: 1033-1042 [PMID: 24665829 DOI: 10.1111/apt.12728]

Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol 2014; 20: 14105-14125 [PMID: 25339800 DOI: 10.3748/wjg.v20.i39.14105]

Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre T, Talley NJ. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61: 1284-1290 [PMID: 22234979 DOI: 10.1136/gutjnl-2011-300474]

Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brünink S, Greuel S, Lehmann M, Hassan O, Aschmann T, Schumann E, Chua RL, Conrad C, Eils R, Stenzel W, Windgassen M, Röller L, Goebel HH, Gelderblom HR, Martin H, Nitsche A, Schulz-Schaeffler WJ, Hakroush S, Winkler MS, Tampe B, Scheife B, Körtvélyessy P, Reinhold D, Siegmund B, Kühn AA, Elezkurtaj S, Horst D, Oesterhelweg L, Tsokos M, Ingold-Heppner B, Stadelmann C, Drosten W, Corman VM, Radbruch H, Heppner FL. Offactory transmucosal SARS-CoV-2 infection as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 2021; 24: 168-175 [PMID: 33257876 DOI: 10.1038/s41593-020-00758-5]

Deigendesch S, Nironi L, Kutza M, Wischnewski S, Fuchs V, Hench J, Frank A, Nienhold R, Mertz KD, Cathomas G, Matter MS, Siegemund M, Tolnay M, Schirmer L, Pröbstel AK, Tzankov A, Deigendesch N, Sanmarco LM, Wheeler MA, Gut-licensed IFNγ+ NK cells drive LAMPI "TRAIL" anti-inflammatory astrocytes. Nature 2021; 590: 473-479 [DOI: 10.1038/s41586-020-03116-4]

Schurink B, Roos E, Radonic T, Barbe E, Bouman CSC, de Boer HH, de Bree GJ, Bulle EB, Dijkgraaf MG, Eils R, Stenzel W, Windgassen M, Röller L, Goebel HH, Gelderblom HR, Martin H, Nitsche A, Schulz-Schaeffler WJ, Hakroush S, Winkler MS, Tampe B, Scheife B, Körtvélyessy P, Reinhold D, Siegmund B, Kühn AA, Elezkurtaj S, Horst D, Oesterhelweg L, Tsokos M, Ingold-Heppner B, Stadelmann C, Drosten W, Corman VM, Radbruch H, Heppner FL. Offactory transmucosal SARS-CoV-2 infection as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 2021; 24: 168-175 [PMID: 33257876 DOI: 10.1038/s41593-020-00758-5]

Acharya A, Kevadiya BD, Gendelman HE, Byrareddy SN. SARS-CoV-2 Infection Leads to Neurological Dysfunction. J Neuroimmun Pharma 2020; 15: 167-173 [PMID: 32447746 DOI: 10.1007/s11481-020-00924-9]

Bercik P, Collins S, Verdu E. Microbes and the gut-brain axis. Neurogastroenterol Motil 2012; 24: 405-413 [DOI: 10.1111/j.1365-2982.2012.01906.x]

Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28: 203-209 [PMID: 25830558]

JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 2012; 9: 286-294 [DOI: 10.1038/nrgastro.2012.32]

Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction 2020 [PMID: 33007104 DOI: 10.1111/add.15276]
symptomatic COVID-19 vs asymptomatic SARS-CoV-2 infection: a case-control study from western Rajasthan, India. Trans R Soc Trop Med Hyg. 2021; 115: 820-831 [PMID: 33444432 DOI: 10.1093/trstmh/trta172]

142 Farsalinos K, Bagos PG, Giannouchos T, Niasara R, Barbouni A, Poulos K. Smoking prevalence among hospitalized COVID-19 patients and its association with disease severity and mortality: an expanded re-analysis of a recent publication. Harm Reduct J 2021; 18: 9 [PMID: 33453726 DOI: 10.1186/s12954-020-00437-5]

143 Meini S, Fortini A, Andreini R, Sechi LA, Tascini C. The Paradox of the Low Prevalence of Current Smokers Among Covid-19 Patients Hospitalized in Non-Intensive Care Wards: Results From an Italian Multicenter Case-Control Study. Nicotine Tob Res 2020 [PMID: 32964233 DOI: 10.1093/ntr/ntaa188]

144 Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol 2020; 11: 1359 [PMID: 32595653 DOI: 10.3389/fimmu.2020.01359]

145 Brinkman DJ, Ten Hove AS, Vervoordeldonk MJ, Luyer MD, de Jonge WJ. Neuroimmune Interactions in the Gut and Their Significance for Intestinal Immunity. Cells 2019; 8 [PMID: 31269754 DOI: 10.3390/cells8070670]

146 Galitovskiy V, Qian J, Chemyavskey AI, Marchenko S, Gindi V, Edwards RA, Grando SA. Cytokine-induced alterations of α7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- vs Th2-mediated colitis. J Immunol 2011; 187: 2677-2687 [PMID: 21784975 DOI: 10.4049/jimmunol.1002711]

147 Matteoli G, Boecxktstens GE. The vagal innervation of the gut and immune homeostasis. Gut 2013; 62: 1214-1222 [PMID: 23023166 DOI: 10.1136/gutjnl-2012-302550]

148 Lunney PC, Leong RW. Review article: Ulcerative colitis, nicotine and cytokine therapy. Aliment Pharmacol Ther 2012; 36: 997-1008 [PMID: 23072629 DOI: 10.1111/apt.12068]

149 Alice H, Massip F, Qi C, Stella de Biase M, van Nijnatten JL, Kersten ETG, Kermani NZ, Kluder B, Vonk JM, Vermeulen RCH, Neighbors M, Tew GW, Grimbaldeston M, ten Hacken NHT, Hu S, Guo Y, Zhang X, Sun K, Hiemstra PS, Ponder BA, Makeka MJ, Malmstrom K, Rintoul RC, Reyfman PA, Theis FJ, Brandsma C-A, Adcock I, Timens W, Xu CJ, van den Berge M, Schwarz RF, Koppelman GH, Nawijn MC, Faiz A. Determinants of SARS-CoV-2 receptor gene expression in upper and lower airways. [Cited February 1, 2021]. 2020 Preprint. Available from: medRxiv: 20169946 [DOI: 10.1101/2020.08.31.20169946]

150 Voinksy I, Gurwitz D. Smoking and COVID-19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current vs never smokers. Drug Dev Res 2020 [PMID: 32757420 DOI: 10.1002/ddr.21729]

151 Boezzaart AP, Botha DA. Treatment of Stage 3 COVID-19 With Transcutaneous Auricular Vagus Nerve Stimulation Drastically Reduces Interleukin-6 Blood Levels: A Report on Two Cases. Neuromodulation 2021; 24: 166-167 [PMID: 33063409 DOI: 10.1111/numo.13293]

152 Ahmad F. COVID-19 induced ARDS, and the role of galantamine to activate the cholinergic anti-inflammatory pathway. Med Hypotheses 2020; 145: 110331 [PMID: 33038588 DOI: 10.1016/j.mehy.2020.110331]

153 Douaoui S, Djidjik R, Boubakeur M, Ghernaout M, Touil-Boukouff C, Oumouna M, Derrar F, Amrani Y. GTS-21, an α7nAChR agonist, suppressed the production of key inflammatory mediators by PMBCs that are elevated in COPD patients and associated with impaired lung function. Immunobiology 2020; 225: 151950 [PMID: 32387130 DOI: 10.1016/j.imbio.2020.151950]

154 Ten Hove AS, Brinkman DJ, Li Yim AYF, Verseijden C, Hakvoort TBM, Admiraal I, Welting O, Brinkman DJ, Li Yim AYF, Verseijden C, Hakvoort TBM, Admiraal I, Welting O, Botha DA. Treatment of Stage 3 COVID-19 With Transcutaneous Auricular Vagus Nerve Stimulation Drastically Reduces Interleukin-6 Blood Levels: A Report on Two Cases. Neuromodulation 2021; 24: 166-167 [PMID: 33063409 DOI: 10.1111/numo.13293]

155 Ahmad F. COVID-19 induced ARDS, and the role of galantamine to activate the cholinergic anti-inflammatory pathway. Med Hypotheses 2020; 145: 110331 [PMID: 33038588 DOI: 10.1016/j.mehy.2020.110331]

156 Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulos K. Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications. Int J Mol Sci 2020; 21 [PMID: 32823591 DOI: 10.3390/ijms21165807]

157 Napping PL, Yang R, Yang H, Tracey KJ, Delade RL, Fink MP, HMGB1 B box increases the permeability of Caco-2 enteroctyic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123: 790-802 [PMID: 12198705 DOI: 10.1053/gast.2002.35391]

158 Leung JM, Yang CX, Sin DD. COVID-19 and nicotine as a mediator of ACE-2. Eur Respir J 2020; 55 [PMID: 32350104 DOI: 10.1183/13993003.01261-2020]

159 Uemura N, Yagi H, Uemura MT, Hatanaka Y, Yamakado H, Takahashi R. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol Neurodegener 2018; 13 [PMID: 29751824 DOI: 10.1186/s13024-018-0257-5]

160 Tassorelli C, Mojoli F, Baldanti F, Bruno R, Benazzo M. COVID-19: what if the brain had a role in causing the death? Eur J Neurol 2020; 27: e41-e42 [PMID: 32333819 DOI: 10.1111/ene.14275]

161 Matschke F, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba M, Heinemann A, Pfefferle S, Schwenbenland M, Sumner Magruder D, Bonn S, Prinz M, Gerloff C, Püscher K, Krasemann S, Aepfelbacher M, Glatzel M. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol
Achilika B, San D, Chaker A, Tall ND, Gueye SB, Ndiaye T, Gueye F. Microbial translocation and TLR4 activation in HIV-infected individuals in a low-resource setting. J Acquir Immune Defic Syndr 2020; 82: 485-490 [PMID: 31859857 DOI: 10.1097/QAI.0000000000001588]

Du Sales A, Lartaud M, Delaporte E, Dreyfus V, Borriss R, Meurice JP, Pottier M. Bacterial translocation in HIV-infected patients: a review. AIDS 2006; 20: 1177-1185 [PMID: 16683170 DOI: 10.1097/01.aids.0000222162.99070.51]

Forbes HJ, Curtis HJ, Hulme WJ, Parry J, Hester F, Harper S, Evans SJW, Smeeth L, Goldacre B. COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet 2020; 396: 1736-1745 [PMID: 33002428 DOI: 10.1016/S0140-6736(20)30684-X]

Aubert P, Virelizier JL, Tissier C, Pi YM, Bulet P, Tazi JK, Michael NL, Wabwire-Mangen F. Differential associations of IL-6 and intestinal fatty acid-binding protein with progressive untreated HIV-1 infection in Rakai, Uganda. AIDS 2016; 30: 327-334 [PMID: 26562149 DOI: 10.1097/QAD.0000000000001192]

Bhaskaran K, Rentsch CT, MacKenna B, Mehrkar A, Yates CJ, Gordon S, Chen MF, Sabin CA, Cooper RV, Collinson P, Purcell PL, Cordingley ML, Vella A, Gazzard BG, Clase CM, Williams T, Wood RJ. Analysis of the impact of smoking on the development of CD4+ cell decline and progression to AIDS in people infected with HIV in England, Wales, and Northern Ireland: a cohort study. Lancet 2012; 380: 821-827 [PMID: 22826903 DOI: 10.1016/S0140-6736(12)60481-5]

Bull DR, Christensen J, Dore CJ, Meltzer MI, editors. The burden of infectious diseases in the United States: a longer view. Vital Health Stat 2001; 13: 1-88 [PMID: 11293347]

Aiken A, Mitchell G, McMichael AJ, editors. Infectious diseases: the burden of disease. World Health Organization, 1999.
